Have questions about our BinaxNOW COVID-19 Self Test?
Here's a step-by-step video guide and answers to some of the questions you might have. https://t.co/xQQotKsi8f
BREAKING: Our BinaxNOW COVID-19 Self Test receives FDA Emergency Use Authorization for asymptomatic, over-the-counter use—no prescription needed.
Learn how frequent testing can help restore a sense of normalcy in everyday settings where people gather: https://t.co/aqPCMYgTHl
More accessible COVID testing than ever!
Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use https://t.co/IG8FqPQcrs
Today we began another year as a #DividendAristocrat, declaring a quarterly #dividend of 45 cents per share—up 25% year over year: https://t.co/VDH29G28OE $ABT
Your support saves lives! Since February 2018, we've reduced the number of deaths from cardiovascular disease by 15% and stroke by 14.3%. And we aren't finished! Thank you for your generous support. https://t.co/mUaZwJyIzh
New study concludes that BinaxNOW facilitates earlier isolation of infectious people and that rapid antigen tests are an important tool to reduce community transmission: https://t.co/RG27zSdhhL (1/3)
Programs prepare Chicago’s future scholars | UChicago Civic Engagement. So proud of my mentee, Nneka Jones, future leader, rainmaker, and role model! #possefoundation https://t.co/7CGTrc4KYs
This is us. We’re not going anywhere.
We’re stepping up, 107,000+ strong, to support communities worldwide with resources and technologies to keep people healthy.
"We build our products as if they’re intended for our own family. I couldn’t think of a more specific situation where that’s so true to us as we look at these tests."
– Robert Ford, our President and CEO, during @WSJTech’s panel, "The Vaccine and Testing Arms Race" #WSJTechLive
"We build our products as if they’re intended for our own family. I couldn’t think of a more specific situation where that’s so true to us as we look at these tests."
– Robert Ford, our President and CEO, during @WSJTech’s panel, "The Vaccine and Testing Arms Race" #WSJTechLive
NEWS: We're releasing ID NOW COVID-19 interim clinical study results from 1,003 people to provide the facts on clinical performance and support public health.
Data show performance of 95.0% sensitivity, 97.9% specificity within 7 days of symptom onset: https://t.co/BIhMVbHaoM
Best-selling author and motivational speaker @JanineDriver reveals the struggles she’s faced during COVID-19 and what she’s doing to overcome the odds. #KYVPandemicReset https://t.co/T0WZM1nSTp
Bloomberg reporting what i hoped for: President will send out 100 million Abbott Labs 15 minute tests, hopefully for schools. This is why i kept saying to own this one, this and the new Glucose Monitor. https://t.co/2Cj9QndmfO i would buy it here.